The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors. Lawmakers ...

Twenty years ago, Congress began hearing that the patent system needed a faster, cheaper way than district court suits to assess the validity of issued patents. In line with this goal, Congress ...